HC Wainwright & Co. Reiterates Buy on XOMA Royalty, Maintains $97 Price Target
3/20/2026
Impact: 80
Healthcare
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on XOMA Royalty (NASDAQ: XOMA) and maintained a price target of $97. This endorsement suggests confidence in the company's future performance.
AI summary, not financial advice
Share: